Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesBeginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Non-cash Items (2017 - 2025)

BioCorRx (BICX) has disclosed Non-cash Items for 9 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items changed N/A to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.7 million for FY2025, N/A changed from the prior year.
  • Non-cash Items hit $1.7 million in Q4 2025 for BioCorRx, up from $1.6 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $1.8 million in Q4 2023 to a low of $813700.0 in Q1 2021.
  • Historically, Non-cash Items has averaged $1.1 million across 5 years, with a median of $871627.0 in 2022.
  • Biggest YoY gain for Non-cash Items was 147.05% in 2021; the steepest drop was 0.67% in 2021.
  • Year by year, Non-cash Items stood at $815351.0 in 2021, then rose by 6.31% to $866766.0 in 2022, then skyrocketed by 103.73% to $1.8 million in 2023, then tumbled by 47.11% to $934026.0 in 2024, then surged by 78.7% to $1.7 million in 2025.
  • Business Quant data shows Non-cash Items for BICX at $1.7 million in Q4 2025, $1.6 million in Q3 2025, and $1.5 million in Q2 2025.